Renal Dysfunction and Clinical Outcomes of Patients Undergoing ICD and CRTD Implantation: Data from the Israeli ICD Registry

Implantable Defibrillators Improve Survival in End-Stage Renal Disease: Results from a Multi-Center Registry

(2010) Swapnil Hiremath et al.   AMERICAN JOURNAL OF NEPHROLOGY

Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure

(2010) Anthony S.L. Tang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Meta-Analysis of Mortality in Dialysis Patients With an Implantable Cardioverter Defibrillator††Disclosures: Dr. Bhatt has received research grants (directly to the institution) from Bristol-Myers Squibb, New York, New York; Eisai Inc., Woodcliff Lake, New Jersey; Ethicon, Inc., Somerville, New Jersey; Heartscape Technologies, Inc., Columbia, Maryland; Sanofi-Aventis, Paris, France; and The Medicines Company, Parsippany, New Jersey. Dr. Bhatt is a consultant for or member of the advisory boards (honoraria waived or donated to nonprofit organizations) of Arena Pharmaceuticals, Inc., San Diego, California; AstraZeneca PLC, London, United Kingdom; Bristol-Myers Squibb; Cardax Pharmaceuticals, Inc., Aiea, Hawaii; Centocor, Inc., Horsham, Pennsylvania; Cogentus Pharmaceuticals, Palo Alto, California; Daiichi Sankyo, Inc., Parsippany, New Jersey; Eisai Inc.; Eli Lilly and Company, Indianapolis, Indiana; GlaxoSmithKline PLC, London, United Kingdom; Johnson & Johnson, New Brunswick, New Jersey; Ortho-McNeil, Raritan, New Jersey; Medtronic, Inc., Minneapolis, Minnesota; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; Otsuka Pharmaceutical Company, Ltd., Tokyo, Japan; ParinGenix, Inc., Weston, Florida; PDL BioPharma, Inc., Redwood City, California; Philips Medical Systems, Andover, Massachusetts; Portola Pharmaceuticals Inc., South San Francisco, California; Sanofi-Aventis; Schering-Plough Corporation, Kenilworth, New Jersey; The Medicines Company; and Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts.

(2009) Rahul Sakhuja et al.   AMERICAN JOURNAL OF CARDIOLOGY

Clinical characteristics and in-hospital outcome of patients with end-stage renal disease on dialysis referred for implantable cardioverter-defibrillator implantation

(2009) Atul Aggarwal et al.   HEART RHYTHM

Increased Central Venous Pressure Is Associated With Impaired Renal Function and Mortality in a Broad Spectrum of Patients With Cardiovascular Disease

(2009) Kevin Damman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Importance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure

(2009) Wilfried Mullens et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease

(2009) Patrick H. Pun et al.   KIDNEY INTERNATIONAL

Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events

(2009) Arthur J. Moss et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic cardiac resynchronization therapy reverses cardiac remodelling and improves invasive haemodynamics of patients with severe heart failure on optimal medical treatment

(2008) T. Inage et al.   EUROPACE

Cardiac Resynchronization Therapy Improves Renal Function in Human Heart Failure With Reduced Glomerular Filtration Rate

(2008) Guido Boerrigter et al.   JOURNAL OF CARDIAC FAILURE

Benefit of Primary Prevention Implantable Cardioverter-Defibrillators in the Setting of Chronic Kidney Disease: A Decision Model Analysis

(2008) MITESH S. AMIN et al.   JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY

Cardiorenal Interactions

(2008) Anju Nohria et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY